Day one sessions covered prediabetes, the newest GLP-1 receptor agonists, tirzepatide and bariatric care, per the organizers' recap.
Recap by typeshit. Post by Facebook on Facebook.
An explainer on how GLP-1 drugs act on reward and craving in the brain, and the research testing them against alcohol, nicotine and other substance use.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
Robert Lufkin MD shares the observational data: an average 16.1 kg lost at six months among 7,297 women, with 62.7% reporting side effects.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
About 180 people will get MRI scans during food and money tasks through March 2027. Noom is funding the research led by neuroscientist Michael Platt.
A brief BusinessWorld Online item touching on the oral Wegovy pill and Hers. Little detail was available beyond the headline.
Loading…